Wuxi Biologics readies Hong Kong relisting

Wuxi PharmaTech is looking to relist its biologic arm in Hong Kong after the group was taken private through a management buyout in late 2015.

Wuxi Biologics readies Hong Kong relisting
Wuxi Pharma plans to list its biologic arm in Hong Kong, 10 years after its New York listing in 2007

Shanghai-headquartered biopharmaceutical firm Wuxi PharmaTech has taken the first step to relist its biologics unit in Hong Kong after filing a listing application with the city’s stock exchange this week.

The plan to list Wuxi Biologics emerged little more than a year after China’s largest contract research organisation delisted from the New York Stock Exchange in December 2015, following a $3.3 billion buyout by a consortium that included company founder...

To continue reading, please login or register for free

Print Edition

FinanceAsia Print Edition

CONFERENCES